103 related articles for article (PubMed ID: 462156)
1. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
Schmieder HA; Jungi WF; Mayr AC; Senn HJ
Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
[TBL] [Abstract][Full Text] [Related]
2. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
3. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
Hansen MM; Bloomfield CD; Jørgensen J; Ersbøll J; Pedersen-Bjergaard J; Blom J; Nissen NI
Cancer Treat Rep; 1980; 64(10-11):1135-7. PubMed ID: 7459900
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of bronchopulmonary small cell carcinoma with a combination of cyclophosphamide and VP-16].
González Larriba JL; Ordóñez Gallego A; Díaz Pérez MA; García de Paredes ML; Zamora P; Montero García JM
Med Clin (Barc); 1984 May; 82(19):836-9. PubMed ID: 6330470
[No Abstract] [Full Text] [Related]
5. [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Jungi WF; Senn HJ; Beckmann C; Flury R; Frei P; Holdener E
Schweiz Med Wochenschr; 1975 Oct; 105(42):1365-9. PubMed ID: 179137
[TBL] [Abstract][Full Text] [Related]
6. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
7. VP-16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report.
Jacobs P; King HS; Cassidy F; Dent DM; Harrison T
Cancer Treat Rep; 1981; 65(11-12):987-93. PubMed ID: 7028260
[TBL] [Abstract][Full Text] [Related]
8. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
Tumori; 1977; 63(2):169-73. PubMed ID: 898287
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
[No Abstract] [Full Text] [Related]
11. Relationship between myelosuppression and chemotherapeutic response in small cell bronchogenic carcinoma.
Holoye PY
Exp Hematol; 1985; 13 Suppl 16():72-9. PubMed ID: 2985416
[TBL] [Abstract][Full Text] [Related]
12. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Newlands ES
Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
[TBL] [Abstract][Full Text] [Related]
13. Role of intravenous hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma.
Valdivieso M; Bodey GP; Benjamin RS; Barkley HT; Freeman MB; Ertel M; Smith TL; Mountain CF
Cancer Treat Rep; 1981; 65 Suppl 5():145-50. PubMed ID: 6809324
[TBL] [Abstract][Full Text] [Related]
14. The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
Banham S; Dorward A; Hutcheon A; Ahmedzai S; Cunningham D; Burnett A; Soukop M; Lucie N; Kaye S
Semin Oncol; 1985 Mar; 12(1 Suppl 2):2-6. PubMed ID: 2983433
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
[TBL] [Abstract][Full Text] [Related]
16. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
[No Abstract] [Full Text] [Related]
17. VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
Morasca L; Marsoni S; Pisoni MB; Piazza E; Vago G; Casali W; Cogo R; Bianchi C; Scapaticci R
Cancer Chemother Pharmacol; 1982; 7(2-3):209-10. PubMed ID: 7083461
[TBL] [Abstract][Full Text] [Related]
18. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
19. [Effects of oral etoposide in small cell carcinoma of the lung].
Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
Sanz Ortíz J; Saiz García F
Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
[No Abstract] [Full Text] [Related]
[Next] [New Search]
